JENAVALVE TECHNOLOGY

HQ - Irvine, CA

Summary

JenaValve is a medical device company developing the first transcatheter heart valve technology that is uniquely designed for the minimally invasive treatment of aortic regurgitation (AR).

Deals Overview

Total Deals2

Valued Deals2

Total Value£ 608 M

Avg. Deal Size£ 304 M

Market Context

Senior Management

John Kilcoyne
CEO

Sort

31 Aug 2022|United States|Medical Equipment

Target: JENAVALVE TECHNOLOGY

Bidder: GIMV NV

9 Service Providers

2 Target | 7 Bidder

10 Dealmakers

2 Target | 8 Bidder

£ 85 M

Value

24 Jul 2024|United States|Medical Equipment

Target: JENAVALVE TECHNOLOGY

Bidder: EDWARDS LIFESCIENCES

7 Service Providers

4 Target | 3 Bidder

16 Dealmakers

4 Target | 12 Bidder

£ 522 M

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy